Patrick Wood
Stock Analyst at Morgan Stanley
(2.27)
# 2,714
Out of 5,141 analysts
121
Total ratings
44.68%
Success rate
-0.35%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $80 → $85 | $84.23 | +0.91% | 9 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $130 → $118 | $74.58 | +58.22% | 8 | Feb 5, 2026 | |
| MDLN Medline | Initiates: Overweight | $48 | $49.80 | -3.61% | 1 | Jan 12, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $84.07 | -1.27% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $134.25 | +0.56% | 3 | Dec 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $17 → $23 | $24.57 | -6.39% | 6 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $8.63 | +15.87% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $27.27 | +87.02% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $73.08 | +2.63% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $185.39 | +13.27% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $19 → $15 | $21.58 | -30.49% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $14 → $21 | $17.94 | +17.06% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $82.63 | -3.18% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $250.65 | +17.69% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $79.78 | +1.53% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $72.94 | +41.21% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $120.27 | -40.13% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $115.45 | +49.85% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $241.89 | +31.05% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $2.26 | +342.48% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $17.76 | +108.33% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $150.73 | - | 5 | Dec 11, 2017 |
GE HealthCare Technologies
Feb 5, 2026
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $84.23
Upside: +0.91%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $130 → $118
Current: $74.58
Upside: +58.22%
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $48
Current: $49.80
Upside: -3.61%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $84.07
Upside: -1.27%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $134.25
Upside: +0.56%
Tandem Diabetes Care
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $17 → $23
Current: $24.57
Upside: -6.39%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $8.63
Upside: +15.87%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $27.27
Upside: +87.02%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $73.08
Upside: +2.63%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $185.39
Upside: +13.27%
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $21.58
Upside: -30.49%
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $17.94
Upside: +17.06%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $82.63
Upside: -3.18%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $250.65
Upside: +17.69%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $79.78
Upside: +1.53%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $72.94
Upside: +41.21%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $120.27
Upside: -40.13%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $115.45
Upside: +49.85%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $241.89
Upside: +31.05%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $2.26
Upside: +342.48%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $17.76
Upside: +108.33%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $150.73
Upside: -